[go: up one dir, main page]

HUP0300241A3 - Processes for preparing torsemide intermediate - Google Patents

Processes for preparing torsemide intermediate

Info

Publication number
HUP0300241A3
HUP0300241A3 HU0300241A HUP0300241A HUP0300241A3 HU P0300241 A3 HUP0300241 A3 HU P0300241A3 HU 0300241 A HU0300241 A HU 0300241A HU P0300241 A HUP0300241 A HU P0300241A HU P0300241 A3 HUP0300241 A3 HU P0300241A3
Authority
HU
Hungary
Prior art keywords
processes
preparing
preparing torsemide
torsemide intermediate
torsemide
Prior art date
Application number
HU0300241A
Other languages
English (en)
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of HUP0300241A2 publication Critical patent/HUP0300241A2/hu
Publication of HUP0300241A3 publication Critical patent/HUP0300241A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HU0300241A 2000-03-20 2001-03-20 Processes for preparing torsemide intermediate HUP0300241A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19065000P 2000-03-20 2000-03-20
US21151000P 2000-06-14 2000-06-14
PCT/US2001/008866 WO2001070226A1 (en) 2000-03-20 2001-03-20 Novel processes for preparing torsemide intermediate

Publications (2)

Publication Number Publication Date
HUP0300241A2 HUP0300241A2 (hu) 2003-06-28
HUP0300241A3 true HUP0300241A3 (en) 2005-11-28

Family

ID=26886305

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300241A HUP0300241A3 (en) 2000-03-20 2001-03-20 Processes for preparing torsemide intermediate

Country Status (15)

Country Link
US (2) US6635765B2 (hu)
EP (1) EP1284733A4 (hu)
JP (1) JP2003527425A (hu)
KR (1) KR20020081482A (hu)
CN (2) CN1203059C (hu)
AU (2) AU4759201A (hu)
CA (1) CA2403382A1 (hu)
CZ (1) CZ20023395A3 (hu)
HR (1) HRP20020819A2 (hu)
HU (1) HUP0300241A3 (hu)
IL (1) IL151837A0 (hu)
NZ (1) NZ521852A (hu)
PL (1) PL370039A1 (hu)
SK (1) SK14802002A3 (hu)
WO (1) WO2001070226A1 (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI20816A (sl) * 1999-08-11 2002-08-31 Teva Pharmaceutical Industries Ltd. Polimorfi torsemid-a
IL149771A0 (en) * 2002-05-21 2002-11-10 Fintech Lab Ltd Process for preparation of torsemide
ITMI20022749A1 (it) * 2002-12-23 2004-06-24 Cosma S P A Nuovo procedimento per la sintesi della tosemide, in particolare della forma ii pura e stabile.
US7378527B2 (en) * 2004-03-16 2008-05-27 Daqing Che Process for the preparation of torsemide and related intermediates
DE102009005095A1 (de) * 2009-01-19 2010-07-22 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Verfahren zur Herstellung von Carbonitriden über Polykondensations- bzw. Sol-Gel-Verfahren unter Verwendung Wasserstoff-freier Isocyanate
CN102432532B (zh) * 2011-11-10 2014-06-18 天津市汉康医药生物技术有限公司 高纯度托拉塞米化合物
CN104370805B (zh) * 2013-08-13 2016-09-07 天津汉瑞药业有限公司 托拉塞米化合物
JP6817952B2 (ja) * 2015-10-29 2021-01-20 あすか製薬株式会社 ピリミジン誘導体
CN110054647B (zh) * 2019-05-23 2021-06-15 上海勋和医药科技有限公司 托拉塞米磷酸酯类前药、其制备方法及组合物
GB202102575D0 (en) 2021-02-23 2021-04-07 Teva Pharmaceutical Industries Ltd Fixed-dose pharmaceutical compositions
CN115010659A (zh) * 2022-06-22 2022-09-06 南京正科医药股份有限公司 一种托拉塞米新杂质对照品及其制备方法
CN115417810B (zh) * 2022-09-22 2023-10-10 南京正科医药股份有限公司 一种托拉塞米晶型ⅰ的精制方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2516025A (en) 1947-03-27 1950-07-18 Westinghouse Electric Corp Ground-relay transmission-line protection
BE758749A (fr) 1969-11-12 1971-05-10 Ciba Geigy Procede de preparation de nouveaux acides pyridine-sulfoniques
US3787573A (en) 1970-03-18 1974-01-22 R Mizzoni Pyridine sulfonic acids as diuretics
US3674794A (en) 1970-03-18 1972-07-04 Ciba Geigy Corp Certain-3-pyridine-sulfonamide derivatives
US3824241A (en) 1970-08-26 1974-07-16 Ciba Geigy Corp Pyridinesulfonic acids
GB1368948A (en) 1970-11-11 1974-10-02 Manuf Prod Pharma Pyridine derivatives
US3904636A (en) 1971-11-09 1975-09-09 Christiaens Sa A 3-sulfonamido-4-phenyl aminopyridines and derivatives
ES436109A1 (es) 1974-04-04 1977-01-01 Christiaens Sa A Procedimiento para la preparacion de nuevos derivados de pi-ridina.
GB1477664A (en) 1974-04-17 1977-06-22 Christiaens Sa A Pyridine derivatives
US4055650A (en) 1974-04-17 1977-10-25 A. Christiaens Societe Anonyme Certain 4-phenoxy(or phenylthio)-3-n-acylated-sulfonamido-pyridines
US4042693A (en) 1975-04-14 1977-08-16 A. Christiaens Societe Anonyme Derivatives of 1,2,4-thiadiazine
GB1593609A (en) 1978-01-31 1981-07-22 Christiaens Sa A Pyridine sulfonamides
DE3529529A1 (de) 1985-08-17 1987-02-19 Boehringer Mannheim Gmbh Verfahren zur herstellung einer stabilen modifikation von torasemid
DE3623620A1 (de) 1986-07-12 1988-01-21 Boehringer Mannheim Gmbh Spritzfertige, waessrige, alkalische injektionsloesungen von torasemid und verfahren zu ihrer herstellung
FR2703051B1 (fr) 1993-03-26 1995-04-28 Adir Nouvelles pyridothiadiazines, leurs procédés de préparation, et les compositions pharmaceutiques qui les contiennent.
US5914336A (en) 1998-06-02 1999-06-22 Boehringer Mannheim Gmbh Method of controlling the serum solubility of orally administered torasemide and composition relating thereto

Also Published As

Publication number Publication date
CN1623987A (zh) 2005-06-08
AU2001247592B2 (en) 2005-08-18
US20020019537A1 (en) 2002-02-14
CZ20023395A3 (cs) 2003-04-16
HUP0300241A2 (hu) 2003-06-28
US6670478B2 (en) 2003-12-30
US20030212277A1 (en) 2003-11-13
PL370039A1 (en) 2005-05-16
IL151837A0 (en) 2003-04-10
NZ521852A (en) 2004-10-29
CA2403382A1 (en) 2001-09-27
SK14802002A3 (sk) 2003-05-02
EP1284733A4 (en) 2003-07-16
US6635765B2 (en) 2003-10-21
HRP20020819A2 (en) 2004-12-31
KR20020081482A (ko) 2002-10-26
CN1423558A (zh) 2003-06-11
EP1284733A1 (en) 2003-02-26
WO2001070226A1 (en) 2001-09-27
JP2003527425A (ja) 2003-09-16
CN1203059C (zh) 2005-05-25
AU4759201A (en) 2001-10-03

Similar Documents

Publication Publication Date Title
EG23914A (en) Process for preparing an antichnolinergic
GB0011120D0 (en) Process
IL148031A0 (en) Torsemide polymorphs
HUP0300160A3 (en) Process for preparing (+)-cis-sertraline
HUP0300241A3 (en) Processes for preparing torsemide intermediate
GB0013793D0 (en) Process
GB0010437D0 (en) Process
GB0125191D0 (en) Process for preparing imadacloprid
HUP0300114A3 (en) Process for preparing flavonoid-derivatives
IL154458A0 (en) Processes for preparing cilostazol
HUP0301649A3 (en) Process for preparing azacycloalkanoylaminothiazoles
HUP0201837A3 (en) Process for preparation n-carboxy-anhydrides
GB0002201D0 (en) Process
IL154457A0 (en) Mircronized torsemide
HU0101332D0 (en) Process for preparing substituted pyridines
GB0016633D0 (en) Process
ZA200207683B (en) Processes for preparing torsemide intermediate.
HUP0204443A3 (en) Process for preparing fluoroformates
GB0001564D0 (en) Process
ZA200207740B (en) Process for preparing alkanesulfonyl pyridines.
GB0006722D0 (en) Process
GB0006837D0 (en) Process
GB0007517D0 (en) Process
GB0009709D0 (en) Process
GB0007005D0 (en) Process

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees